100 mg of Remogliflozin, 50 mg of Vildagliptin, and 500/1000 mg of Metformin in a fixed dosage to be given twice daily to help patients enhance their glycemic control. Remo MV and Remozen MV are the two brand names used by the pharmaceutical company to launch the drug. The pharmaceutical company highlighted its first step in FDC medication in a statement. It said, “Glenmark is the first company in the world to launch Remogliflozin + Vildagliptin + Metformin fixed dose combination (FDC) and India is the first country to get access to this FDC drug”.
pharmafranchiseworld.com
The current products in the same medicine category have an average daily cost of therapy of roughly INR 75, but Glenmark’s product has been released for a price of INR 16.50 per pill, which is advised to be taken twice daily, resulting in a daily cost of therapy of INR 33. Alok Malik, Vice President and Business Head of Glenmark India Formulations Group, spoke about the company’s focus on the diabetes drug market. He said, “Diabetes is a key focus area for Glenmark and we have been at the forefront in providing access to the latest treatment options to diabetes patients in India”.
In September 2021, the DCGI granted the business authorisation to manufacture and commercialize this fixed dose combination. SGLT2 and DPP4 inhibitors are becoming the recommended therapy choices for Type 2 diabetes management across the world. As of 2019, the International Diabetes Federation (IDF) estimates that approximately 7.7 crore individuals have diabetes.
